9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock

Rhea-AI Summary

9 Meters Biopharma (NASDAQ: NMTR) announced the closing of an underwritten public offering of 53,076,924 shares at $0.65 per share, yielding approximately $32 million in net proceeds. These funds will support the clinical development of NM-002 for short bowel syndrome and larazotide for celiac disease, along with general corporate purposes. The offering was conducted under an effective shelf registration statement.

Positive

• Net proceeds of approximately $32 million will fund the development of NM-002 and larazotide.
• Expansion of clinical trials for innovative treatments in gastroenterology.

Negative

• Potential dilution of existing shares from the public offering.
• Risks related to the success of product candidates and regulatory approvals.

RALEIGH, NC / ACCESSWIRE / December 15, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $0.65 per share.

The net proceeds to the Company from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by 9 Meters, were approximately $32 million. The Company intends to use the net proceeds of this offering, together with other available funds, to advance the clinical development of NM-002 for the treatment of short bowel syndrome, the continued clinical development of larazotide for the treatment of celiac disease, and for working capital and general corporate purposes.

William Blair & Company, L.L.C. and Truist Securities, Inc. acted as joint book-running managers for the offering. Oppenheimer & Co., Inc. acted as lead manager for the offering and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-manager for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-249268) that was declared effective by the Securities and Exchange Commission (the "SEC") on October 9, 2020. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing prospectus@williamblair.com, or from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, or emailing TruistSecurities.prospectus@Truist.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a rare and unmet needs-focused gastroenterology company. The Company is working to advance NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for Short Bowel Syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3-stage tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-Looking Statements

This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the Company's expected use of the net proceeds from the offering and its need to raise additional capital even after this offering; (ii) uncertainties associated with the clinical development and regulatory approval of product candidates; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended September 30, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Corporate contacts

Edward J. Sitar, Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media contact

Amy Jobe, Ph.D.
LifeSci Communications, LLC
ajobe@lifescicomms.com
315-879-8192

Investor contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma

View source version on accesswire.com:
https://www.accesswire.com/620965/9-Meters-Biopharma-Inc-Announces-Closing-of-Offering-of-Common-Stock

FAQ

What is the size and price of the recent offering by 9 Meters Biopharma (NMTR)?

9 Meters Biopharma closed an offering of 53,076,924 shares at $0.65 per share.

How much funding did 9 Meters Biopharma raise from the recent offering?

The offering raised approximately $32 million in net proceeds.

What will 9 Meters Biopharma use the proceeds from the offering for?

The proceeds will be used for advancing clinical development of NM-002 and larazotide, as well as for working capital.

When was the offering of 9 Meters Biopharma (NMTR) completed?

The offering was completed on December 15, 2020.

What are the potential risks associated with the recent offering by NMTR?

Risks include potential dilution of shares and uncertainties in clinical trial outcomes.